Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis, which result in thrombocytopenia, hemolytic anemia, and tissu...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Marie Scully, Spero R. Cataland, Flora Peyvandi, Paul Coppo, Paul Knöbl, Johanna A. Kremer Hovinga, Ara Metjian, Javier de la Rubia, Katerina Pavenski, Filip Callewaert, Debjit Biswas, Hilde De Winter, Robert K. Zeldin
Médium: Artigo
Jazyk:angličtina
Vydáno: 2019
On-line přístup:https://doi.org/10.1056/nejmoa1806311
https://www.nejm.org/doi/pdf/10.1056/NEJMoa1806311?articleTools=true
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Internet

https://doi.org/10.1056/nejmoa1806311
https://www.nejm.org/doi/pdf/10.1056/NEJMoa1806311?articleTools=true

Podobné jednotky